亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Comparative efficacy and safety of biologic agents in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: A Bayesian network meta-analysis of randomized controlled trials.

医学 托珠单抗 阿巴塔克普 类风湿性关节炎 不利影响 美罗华 内科学 托法替尼 安慰剂 随机对照试验 肿瘤坏死因子抑制剂 塞库金单抗 药理学 阿达木单抗 银屑病性关节炎 淋巴瘤 病理 替代医学
作者
Yoon‐Kyoung Sung,Young Ho Lee
出处
期刊:International Journal of Clinical Pharmacology and Therapeutics [Dustri-Verlag]
卷期号:60 (1): 13-23 被引量:1
标识
DOI:10.5414/cp204036
摘要

This study aimed to evaluate the relative efficacy and safety of biologic agents in patients with rheumatoid arthritis (RA) who show inadequate response to tumor necrosis factor (TNF) inhibitors.A meta-analysis with the Bayesian network, combining direct and indirect randomized controlled trial (RCT) data, was conducted to examine the efficacy and safety of abatacept, rituximab, tocilizumab, sarilumab, sirukumab, and secukinumab in patients with RA who showed inadequate response to TNF inhibitors.8 RCTs enrolling a total of 3,617 patients fulfilled the inclusion criteria. More significant American College of Rheumatology 20% (ACR20), ACR50, and ACR70 responses were obtained using therapies similar to these biologics than with placebo. Ranking probability based on surface under the cumulative ranking curve (SUCRA) indicated that tocilizumab was probably the best treatment for ACR20 response, followed by rituximab, abatacept, sarilumab, sirukumab, secukinumab 150 mg, secukinumab 75 mg, and placebo. Furthermore, identical distribution trends were observed for ACR50 response rates. In comparison, ACR70-based SUCRA rating revealed that rituximab, followed by tocilizumab, abatacept, sirukumab, secukinumab 150 mg, sarilumab, secukinumab 75 mg, and placebo might potentially result in ACR70. There was no significant difference between the number of adverse events and severe adverse events between the treatments.All biologic agents studied were effective in treating patients with TNF inhibitor-refractory RA; however, tocilizumab, rituximab, and abatacept appeared to be more efficient than sarilumab, sirukumab, and secukinumab. There were no differences between the treatments with respect to safety.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhen完成签到,获得积分10
17秒前
哈尔滨完成签到,获得积分20
19秒前
28秒前
米奇妙妙屋完成签到,获得积分10
1分钟前
tylscxf完成签到,获得积分10
1分钟前
YifanWang完成签到,获得积分0
1分钟前
量子星尘发布了新的文献求助30
1分钟前
1分钟前
启震发布了新的文献求助10
1分钟前
1分钟前
1分钟前
2分钟前
2分钟前
www完成签到,获得积分20
2分钟前
2分钟前
风车术完成签到,获得积分20
2分钟前
2分钟前
风车术发布了新的文献求助10
2分钟前
shinian发布了新的文献求助10
2分钟前
2分钟前
小岩完成签到 ,获得积分10
2分钟前
wanci应助风车术采纳,获得10
2分钟前
2分钟前
为神指路发布了新的文献求助30
2分钟前
2分钟前
2分钟前
为神指路完成签到,获得积分20
2分钟前
2分钟前
2分钟前
33完成签到,获得积分0
3分钟前
共享精神应助科研通管家采纳,获得20
3分钟前
量子星尘发布了新的文献求助10
3分钟前
行走完成签到,获得积分10
4分钟前
4分钟前
4分钟前
姚老表完成签到,获得积分10
4分钟前
mashibeo完成签到,获得积分10
4分钟前
4分钟前
量子星尘发布了新的文献求助10
4分钟前
脑洞疼应助zhiweiyan采纳,获得10
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976649
求助须知:如何正确求助?哪些是违规求助? 3520756
关于积分的说明 11204729
捐赠科研通 3257502
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629